



ASX ANNOUNCEMENT

Consulting CSO, changing arrangements

Brisbane, 29th May 2015: Tissue Therapies announces that Professor Zee Upton will leave her long term role as Consulting Chief Scientific Officer effective 30 June 2015 in order to take up the position of Research Director at the Institute of Medical Biology in A*STAR (Agency for Science Technology and Research) in Singapore. TIS is currently putting in place a new arrangement with Professor Upton whereby she will advise the board on scientific matters.

Professor Upton was instrumental in creating the intellectual property, the formation of the company and has provided strong scientific leadership for Tissue Therapies throughout its journey.

"I am proud of our accomplishments at Tissue Therapies and QUT. It has been a great experience working with such a dedicated team, and having the tenacity to pursue the goal of taking VitroGro to market."

The contract research services provided by QUT has been essential in TIS achieving clearance in the pre-clinical area with both the EMA and the US FDA.

Cherrell Hirst, the Interim Chairman, praised Professor Upton's contribution saying "The Board expresses its sincere thanks to Professor Upton for her significant contribution to TIS over the years since 2003 and for her role in fostering our relationships with the scientific community. We look forward to continuing our deep and important relationship with her in her new role."

As part of an ongoing transition, Tissue Therapies' Director of Research and Development, Dr Gary Shooter who is a seasoned life science professional, will be responsible for scientific operations. Dr Shooter has worked closely with Professor Upton since 2004, has been intimately involved in the development of the VitroGro technology and is well positioned to ensure continuity.

Cherrell Hirst
Interim Chairman

- ENDS -



For more information

<p>Dr Cherrell Hirst, Interim Chairman Tissue Therapies Limited Cherrell@hirst.com</p> <p>Nigel Johnson, Acting CEO Tissue Therapies Limited Tel: +61 7 3334 3900 Email: n.johnson@tissuetherapies.com</p>	<p>Kyahn Williamson Buchan Consulting Tel: +61 (3) 9866 4722 Email: kwilliamson@buchanwe.com.au</p>
---	--

About Tissue Therapies Limited

Tissue Therapies Limited is a biomedical technology company that is developing significantly more effective treatments for acute and chronic wound healing applications, including chronic skin ulcers and burns.

Tissue Therapies Limited is commercialising VitroGro® ECM, a technology created by cell biology, tissue engineering and protein engineering experts at the Institute of Health and Biomedical Innovation at the Queensland University of Technology. The company also has a licence for commercialisation of various patent families related to wound healing and other therapeutic uses. Tissue Therapies Limited's shares are traded on the Australia, Berlin and Frankfurt stock exchanges. For more information, please visit www.tissuetherapies.com.